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Abstract: Previous studies have suggested a benefit for patients with plaque psoriasis when 
omega-3 fatty acids are added to topical treatment. This study evaluated the efficacy of a 
nutritional complement rich in omega-3 fatty acids in patients with mild or moderate plaque 
psoriasis. Thirty patients were recruited, 15 of whom were given topical treatment with   tacalcitol, 
forming the control group. The remaining 15 patients were given topical tacalcitol and 2 capsules 
of Oravex® daily. Three visits, the baseline, intermediate (week 4), and final (week 8), were held 
over an 8-week period. The main efficacy endpoints were the Psoriasis Area and Severity Index 
(PASI), Nail Psoriasis Severity Index (NAPSI) and Dermatological Life Quality Index (DLQI). 
A clear and significant improvement was observed in all the efficacy endpoints in both groups 
between the baseline visit and the end visit. This improvement was significantly greater in the 
group treated additionally with Oravex® than in the control group. Supplementary treatment 
with omega-3 fatty acids complements topical treatment in psoriasis, and makes a significant 
contribution to reducing PASI and NAPSI and improving DLQI; and to reducing scalp lesion 
and pruritus, erythema, scaling, and infiltration of the treated areas.
Keywords: psoriasis, metabolic syndrome, vitamin D derivates, omega-3 fatty acids, 
tacalcitol
Introduction
Psoriasis is a chronic skin disease which shows a course with outbreaks and presents 
variable clinical findings.1 Nowadays, psoriasis is regarded as an immunologically 
based disease which combines dermal inflammation with secondary epidermal 
hyperplasia.2
In recent years, the so-called metabolic syndrome has been described, and defined 
as the ensemble of cardiovascular risk factors, including central obesity, atherogenic 
dyslipidemia, hypertension, and glucose intolerance, affected by lifestyle, genetic 
predisposition, and the environment. The presence of metabolic syndrome triples a 
patient’s risk of developing type 2 diabetes mellitus and doubles the risk of developing 
cardiovascular disease.3
It has been described that patients diagnosed with psoriasis have a high prevalence 
of metabolic disorders such as diabetes, hypertension, obesity, and hyperlipidemia, 
as well as a high frequency of tobacco consumption, and also an increased morbidity 
and mortality risk.4–6
Like psoriasis, metabolic syndrome is characterized by a fundamentally 
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with metabolic syndrome due to a shared inflammation 
mechanism. Another possible explanation for predisposition 
to the development of metabolic syndrome by patients with 
psoriasis lies in behavioral habits or in the psychological 
impact of the disease. Another hypothesis is that it is the 
actual metabolic syndrome that promotes development of 
psoriasis.
In relation to the foregoing, several studies have 
  demonstrated an increase in C-reactive protein in patients 
with psoriasis due to an elevation in the serum concentration 
of IL-6 and MRP8 and MRP14 proteins, which presents 
proatherogenic action.4 Recent studies confirm that Th17, 
Th22, and Th1 cells are detected in psoriatic skin lesions 
and implicated in psoriasis pathogenesis.7
In recent years, the topical treatment of psoriasis has 
made major progress.8–10 Vitamin D derivatives are one of 
the pillars of topical treatment of psoriasis.11–15 In Spain 3 
vitamin D derivatives are used: calcipotriol, tacalcitol, and 
calcitriol. In combination with other treatments, vitamin D 
derivatives constitute the ideal maintenance treatment, since 
their application may be maintained over time.
Omega-3 fatty acids, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), reduce symptoms in many 
inflammatory skin diseases, limiting the spreading of the 
inflammatory process.16,17 In the skin, the main route for 
the synthesis of leukotrienes is 15-lipoxygenase, giving 
rise to 15-hydroxyeicosatetraenoic acid. Moreover, the 
epidermis can convert the leukotriene A4 (produced by the 
polymorphonuclear leukocytes) into leukotriene B4, one of 
the main inflammation mediators.
The intake of EPA and DHA leads to the   formation 
of hydroxylated metabolites through 15-  lipoxygenase, 
15-  hydroxyeicosapentaenoic acid, and 15-hydroxydoco-
sahexaenoic acid. Both substances are potent inhibitors of 
the 5-lipoxygenase of mononuclear cells, thus limiting the 
synthesis of proinflammatory leukotrienes LTB4, LTC4, 
and LTD4.
To date, several studies have been performed to evaluate 
the efficacy of the daily supplementation of EPA and DHA in 
patients with psoriasis,17–20 with an improvement observed in 
their mean Psoriasis Area and Severity Index (PASI) score, 
as well as in clinical symptoms, particularly in pruritus.
Objective
The study endpoint is to evaluate the efficacy of the intake 
of omega-3 fatty acids in patients with mild or moderate 
plaque psoriasis by means of the addition of Oravex® (Thea 
Laboratories, Barcelona, Spain [280 mg of eicosapentaenoic 
acid, 40 mg of docosahexaenoic acid, 50 mg of thyme extract, 
50 mg of olive leaf extract, 20 mg of green tea extract, 7.5 mg 
of zinc, 27.5 µg of selenium per capsule]), as a nutritional 
complement rich in omega-3 fatty acids, increases the effi-
cacy of topical treatment of plaque psoriasis.
Methodology
This was a prospective, open, single-center, controlled 
observational study with a 2-month follow-up.
Fifteen patients were selected during October and 
November 2007 and began treatment with tacalcitol, forming 
group B. In turn, a further 15 patients were selected who, 
besides treatment with tacalcitol, took 2 daily capsules of 
Oravex®, forming group A. There was no placebo in the study, 
so the study was not blinded to either the patient or to the 
observer. Both groups were homogenous for sex, age, and 
body mass index (BMI). The dosage of EPA and DHA was 
640 mg daily (the World Health Organization recommends 
a minimum daily intake of 0.3 to 0.5 g of EPA and DHA in 
the general population).
The inclusion criteria were age between 18 and 70 years, 
and stable mild (PASI , 3) or moderate (PASI 3–10) plaque 
psoriasis. The exclusion criteria were receiving topical 
therapy in the previous 2 weeks and phototerapy, systemic, or 
biological therapy in the previous 4 weeks. Also we excluded 
pregnant or breastfeeding women, and patients with liver 
disease and neuropathies.
The main efficacy endpoints were PASI, Nail Psoriasis 
Severity Index (NAPSI), and Dermatology Life Quality 
Index (DLQI).
Secondary endpoints were the values pertaining to the 
presence of pruritus (yes/no), scalp psoriasis (0, no; 1, mild; 
2, moderate; 3, severe) and clinical evolution of the target 
plaque according to erythema, infiltration, and scaling (scored 
on a scale of 0, none to 5, serious).
Blood analyses were performed on the patients at the 
baseline and end visits.
Results
Data were collected from the 30 patients at the baseline visit 
and weeks 4 and 8 (Table 1). No patient dropped out or was 
withdrawn from the study.
The mean age was 58.97 ± 15.1 years, 63.3% were 
men, and mean BMI was 26.85 ± 3.3 kg/m2; 30.0% of 
the patients had a normal BMI, 53.3% were overweight, and 
the remaining 16.7% were considered obese.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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The safety endpoints, particularly in blood control, 
  presented no deterioration in patient state rendering 
withdrawal from the study advisable.
The PASI presented an improvement of 6.8 points in 
the Oravex® group, whereas in the control group it was only 
3.5 points (Figure 1). This difference was highly significant 
(P , 0.0001).
A reduction was observed in the NAPSI in the group 
treated with Oravex®, from 2.91 at the baseline visit to 1.68 in 
the visit after 8 weeks. The control group did not improve in 
this endpoint, although this endpoint was initially very low 
and different to that of group A (Figure 2).
DLQI was also greater in the group treated with Oravex®, 
with an improvement of 6.67 points versus 3.03 in the control 
group (Figure 3).
In all the secondary endpoints studied (scalp lesion, 
lesion of target plaque-erythema, infiltration, and scaling) a 
significant improvement was observed in the group treated 
Table 1 Results of primary and secondary endpoints
Baseline  
visit week 0
Intermediate  
visit week 4
End visit  
week 8
Difference  
baseline–end
Significance  
baseline–end
PASI
Tacalcitol 8.53 6.53 5 −3.53 P , 0.0001
Tacalcitol + Oravex 9.6 5.4 2.8 −6.8
NAPSI
Tacalcitol 0.38 0.43 0.38 0 P = 0.0480
Tacalcitol + Oravex 2.91 2.45 1.68 −1.23
DLQI
Tacalcitol 5.67 3.67 2.64 −3.03 P = 0.0056
Tacalcitol + Oravex 8.53 2.63 1.86 −6.67
Scalp lesion
Tacalcitol 0.6 0.53 0.6 0 P = 0.0038
Tacalcitol + Oravex 0.87 0.8 0.27 −0.6
Pruritus
Tacalcitol 66.7% 40.0% 26.7% −40%
Tacalcitol + Oravex 80.0% 6.7% 0% −80% P , 0.0001
Lesion of target plaque
Erythema
Tacalcitol 2.20 1.80 1.47 −0.73 P = 0.0080
Tacalcitol + Oravex 2.93 1.80 1.13 −1.80
Infiltration
Tacalcitol 1.53 0.93 0.53 −1.0 P = 0.0011
Tacalcitol + Oravex 2.47 1.13 0.47 −2.0
Scaling
Tacalcitol 1.60 0.87 0.20 −1.40 P = 0.0291
Tacalcitol + Oravex 2.27 1.00 0.13 −2.14
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Figure 2 Evolution of nail psoriasis severity index in control group and Oravex® 
group.
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Figure 1 Evolution of psoriasis area and severity index in control group and Oravex® 
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with Oravex® compared with the control group after 8 weeks 
of treatment.
The evolution of some of the patients of the group treated 
with Oravex® plus tacalcitol is shown in Figures 4 and 5.
Discussion
The present study was conducted to evaluate the efficacy 
of the addition of a nutritional supplement rich in omega-3 
fatty acids in the treatment of psoriasis. Previous studies 
have demonstrated the possible effect of the diet on the 
evolution of the disease. Dietary omega-3 (n-3) fatty acids 
have a variety of anti-inflammatory and immune-modulating 
effects that may be of relevance to atherosclerosis and its 
clinical manifestations of myocardial infarction, sudden 
death, and stroke. A variety of biologic effects of EPA and 
DHA have been demonstrated from feeding studies with fish 
or fish oil supplements in humans and animals. These include 
effects on triglycerides, high-density lipoprotein cholesterol, 
platelet function, endothelial and vascular function, blood 
pressure, cardiac excitability, measures of oxidative stress, 
pro- and anti-inflammatory cytokines, and immune function. 
Clinically important anti-inflammatory effects in man are 
further suggested by trials demonstrating benefits of fatty 
acids in psoriasis, among others.²¹
After 8 weeks of treatment, there was a clear improvement 
in all the study endpoints in the group with Oravex® added to 
the treatment with tacalcitol versus the control group, treated 
exclusively with tacalcitol.
Despite the low number of patients recruited to the study, 
the statistical significance of the differences between groups 
clearly indicates that a global improvement is achieved with 
the addition of Oravex® to the treatment with tacalcitol.
Conclusion
Supplementary treatment with omega-3 fatty acids 
complements topical treatment in psoriasis, and makes a 
significant contribution to reducing PASI and NAPSI, and 
improving DLQI; and in reducing scalp lesion and pruritus, 
erythema, scaling, and infiltration of the treated areas.
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